{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:36:12Z","timestamp":1757705772411},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6582,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1995,3]]},"abstract":"<jats:p><jats:italic>The negative inotropic and chronotropic effects of \u03b2\u2010blocker therapy have been reported to reduce morbidity and mortality in patients with Marfan syndrome; however, little is known about the pharmacokinetics of atenolol after oral administration of multiple doses to patients with the Marfan syndrome. We studied the pharmacokinetics of atenolol in 13 such patients aged 18.7 \u00b1 2.9 years who were receiving 1.78 \u00b1 0.58 mg\/kg\/day (70.1 \u00b1 20.3 mg\/m<jats:sup>2<\/jats:sup>\/day) of atenolol for 6 weeks or longer. Mean \u00b1 SD percentage change in baseline heart rate after the administration of atenolol was \u221218.03 \u00b1 16.59% and mean \u00b1 SD percentage change in exercise heart rate after atenolol was \u221233.22 \u00b1 14.75% (<\/jats:italic>P &lt; <jats:italic>.01). Six to 8 atenolol serum concentrations were collected in each patient during a 12\u2010hour dosing interval and were determined by high\u2010performance liquid chromatography with ultraviolet detection. Serum atenolol concentrations at 0 (123 \u00b1 70 \u03bcg\/L) and 12 (116 \u00b1 66 \u03bcg\/L) hours were within 20% of each other and were thus assumed to be at steady\u2010state. A one\u2010compartment, steady\u2010state pharmacokinetic model with first\u2010order absorption and elimination was fitted to the concentration\u2010time data for each patient using nonlinear regression. Maximal concentration was 343 \u00b1 120 \u03bcg\/L, and the mean half\u2010life was 4.72 hours. Pharmacokinetic parameters were as follows: Absorption rate constant (k<jats:sub>a<\/jats:sub>&gt;) was 1.03 \u00b1 1.34 hr<jats:sup>\u22121<\/jats:sup>; elimination rate constant (k) was 0.230 \u00b1 0.220 hr<jats:sup>\u22121<\/jats:sup>; the ratio of bioavailability to volume of distribution (f\/V<jats:sub>d<\/jats:sub>) was 0.00612 \u00b1 0.00214 L<jats:sup>\u22121<\/jats:sup>; area under the concentration\u2010time curve at steady\u2010state (AUC) was 2919 \u00b1 1175 \u03bcghr\/L; and the time at which the highest concentration occurred (t<jats:sub>max<\/jats:sub>) was 1.87 \u00b1 0.16 hours. Additionally, the dose\u2010normalized AUC ranged from 20.9 to 57.8 \u03bcg hr\/L. Although there was considerable variability in the pharmacokinetics of atenolol in patients with the Marfan syndrome, the variability was similar to that reported in patients without Marfan syndrome<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1995.tb04057.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:10:23Z","timestamp":1362769823000},"page":"268-274","source":"Crossref","is-referenced-by-count":3,"title":["Absorption Pharmacokinetics of Atenolol in Patients with the Marfan Syndrome"],"prefix":"10.1002","volume":"35","author":[{"given":"Stephanie J.","family":"Phelps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce S.","family":"Alpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jewel L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"51","volume-title":"The Heritable Disorders of Connective Tissue.","author":"Godfrey M","year":"1993"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010043231402"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(91)90264-F"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.10.4486"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007193230303"},{"key":"e_1_2_1_7_2","first-page":"652","article-title":"Cosegregation of elastin\u2010associated microfibrillar\u2010fiber system in the Marfan syndrome","volume":"46","author":"Godfrey M","year":"1990","journal-title":"Am J Hum Gen"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115589"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/352330a0"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/2.7.961"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/352337a0"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115766"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.13.5917"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197904053001406"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197204132861502"},{"key":"e_1_2_1_16_2","first-page":"123","article-title":"A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on the survivorship without treatment","volume":"129","author":"Halpern BL","year":"1971","journal-title":"John Hopkins Med J"},{"issue":"11","key":"e_1_2_1_17_2","first-page":"365","article-title":"Propranolol retards aortic root\u2010dilation in the Marfan syndrome","volume":"68","author":"Pyeritz RE","year":"1983","journal-title":"Circulation"},{"key":"e_1_2_1_18_2","first-page":"653","article-title":"Long\u2010term clinical experience with atenolol\u2010a new selective \u03b2\u20101 blocker with few side effects from the central nervous system","volume":"65","author":"Henningsen NC","year":"1979","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(79)90229-1"},{"key":"e_1_2_1_20_2","first-page":"562","article-title":"A packaged computer program for pharmacokinetic modeling","volume":"30","author":"Metzler CM","year":"1984","journal-title":"Biometrics"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979254408"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1995.tb04057.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1995.tb04057.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T11:25:37Z","timestamp":1696159537000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1995.tb04057.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["10.1002\/j.1552-4604.1995.tb04057.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04057.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}